Endocrinologia: efeitos da terapia combinada com metformina e agonistas do GLP-1 na redução do peso corporal em pacientes com diabetes tipo 2
DOI:
https://doi.org/10.18378/rebes.v14i3.10839Abstract
This article addressed the efficacy of the combined therapy with metformin and GLP-1 agonists in reducing body weight in patients with type 2 diabetes, a condition that presents challenges in glycemic control and weight management. Type 2 diabetes, often associated with obesity, requires therapeutic interventions that control blood glucose levels and promote weight loss, an indispensable factor for improving clinical outcomes. In this context, the central problem investigated was the efficacy of this combined therapy compared to the isolated use of each agent, particularly concerning weight reduction and glycemic control. The objectives of this study were to review the available scientific literature on the effects of the combined therapy, evaluate the mechanisms of action of each drug, and analyze the results obtained in terms of weight loss and glycemic control. The methodology adopted consisted of a literature review, which included the selection of randomized clinical trials, systematic reviews, and meta-analyses published in recognized databases such as PubMed and Cochrane Library. The inclusion criteria focused on studies that investigated patients with type 2 diabetes treated with the combination of metformin and GLP-1 agonists, while the exclusion criteria eliminated studies that did not present specific data on weight reduction. The results obtained indicated that the combined therapy resulted in greater weight reduction compared to the isolated use of the agents, in addition to providing more robust glycemic control and a favorable safety profile. These findings confirmed the efficacy and safety of the combined therapy, highlighting its relevance in the integrated management of type 2 diabetes. It was concluded that the combination of metformin and GLP-1 agonists is an effective therapeutic strategy for patients who require interventions that address both glycemic control and weight reduction, contributing to improved clinical outcomes and patients' quality of life.
Downloads
References
ACIERNO, Carlo et al. Nonalcoholic fatty liver disease and type 2 diabetes: Pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine, v. 1, n. 5, p. 287-306, 2020.
ALLIN, Kristine H.; NIELSEN, Trine; PEDERSEN, Oluf. Mechanisms in endocrinology: Gut microbiota in patients with type 2 diabetes mellitus. European journal of endocrinology, v. 172, n. 4, p. R167-R177, 2015.
BAHNE, Emilie et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI insight, v. 3, n. 23, 2018.
BUSCH, Robert S.; KANE, Michael P. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgraduate medicine, v. 129, n. 7, p. 686-697, 2017.
CASTANHOLA, Maria Eduarda; PICCININ, Adriana. Fisiopatologia da diabetes e mecanismo de ação da insulina revisão de literatura. In: IX JORNACITEC-Jornada Científica e Tecnológica, v.9, n.1, 2020.
CHATTERJEE, Sudesna; KHUNTI, Kamlesh; DAVIES, Melanie J. Type 2 diabetes. The lancet, v. 389, n. 10085, p. 2239-2251, 2017.
CIGNARELLI, Angelo et al. Tessuto adiposo, obesità e diabete. Il Diabete Online Soc. Ital. Diabetol. Rassegna, v. 29, 2017.
DEFRONZO, Ralph A. Pathogenesis of type 2 diabetes mellitus. International textbook of diabetes mellitus, p. 371-400, 2015.
DURRUTY, Pilar; SANZANA, María; SANHUEZA, Lilian. Pathogenesis of type 2 diabetes mellitus. In: Type 2 Diabetes-From Pathophysiology to Modern Management. IntechOpen, 2019.
FERRAÙ, Francesco et al. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Frontiers in endocrinology, v. 9, p. 358, 2018.
FORETZ, Marc; GUIGAS, Bruno; VIOLLET, Benoit. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology, v. 15, n. 10, p. 569-589, 2019.
GALICIA-GARCIA, Unai et al. Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences, v. 21, n. 17, p. 6275, 2020.
GILLANI, Syed Wasif et al. Effect of metformin on lipid profiles of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Journal of Pharmacy and Bioallied Sciences, v. 13, n. 1, p. 76-82, 2021.
GIRARD, Jean. Glucagon, a key factor in the pathophysiology of type 2 diabetes. Biochimie, v. 143, p. 33-36, 2017.
GURUNG, Manoj et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine, v. 51, 2020.
HINNEN, Deborah. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes spectrum, v. 30, n. 3, p. 202-210, 2017.
HURTADO, Maria Daniela; VELLA, Adrian. What is type 2 diabetes?. Medicine, v. 47, n. 1, p. 10-15, 2019.
LEE, Chae Bin et al. The relationship between the gut microbiome and metformin as a key for treating type 2 diabetes mellitus. International journal of molecular sciences, v. 22, n. 7, p. 3566, 2021.
LINGVAY, Ildiko et al. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. The Lancet, v. 399, n. 10322, p. 394-405, 2022.
MACEDO, Geisa Maria Campos; NUNES, Samanta; BARRETO, Tania. Skin disorders in diabetes mellitus: an epidemiology and physiopathology review. Diabetology & metabolic syndrome, v. 8, p. 1-8, 2016.
MARÍN-PEÑALVER, Juan José et al. Update on the treatment of type 2 diabetes mellitus. World journal of diabetes, v. 7, n. 17, p. 354, 2016.
MARUTHUR, Nisa M. et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Annals of internal medicine, v. 164, n. 11, p. 740-751, 2016.
NAUCK, Michael A. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Molecular metabolism, v. 46, p. 101102, 2021.
NUNES, J. Silva. Fisiopatologia da diabetes mellitus tipo 1 e tipo 2. Portugal P, editor, v. 100, p. 8-12, 2018.
OLIVEIRA, Mariana Sales et al. Diabetes Mellitus tipo 2-uma revisão abrangente sobre a etiologia, epidemiologia, fisiopatologia, diagnóstico e tratamento. Brazilian Journal of Health Review, v. 6, n. 5, p. 24074-24085, 2023.
PETRONI, Maria Letizia et al. Combination of GLP‐1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. Endocrinology, Diabetes & Metabolism, v. 2, n. 4, p. e00082, 2019.
PRASAD, Rashmi B.; GROOP, Leif. Genetics of type 2 diabetes—pitfalls and possibilities. Genes, v. 6, n. 1, p. 87-123, 2015.
RAMRACHEYA, Reshma et al. GLP‐1 suppresses glucagon secretion in human pancreatic alpha‐cells by inhibition of P/Q‐type Ca2+ channels. Physiological reports, v. 6, n. 17, p. e13852, 2018.
RODRIGUES NETO, Edilson Martins et al. Metformina: uma revisão da literatura. Saúde e Pesquisa, v. 8, n. 2, p. 355-362, 2015.
RYAN, Donna; ACOSTA, Andres. GLP‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity, v. 23, n. 6, p. 1119-1129, 2015.
SANCHEZ-RANGEL, Elizabeth; INZUCCHI, Silvio E. Metformin: clinical use in type 2 diabetes. Diabetologia, v. 60, p. 1586-1593, 2017.
SCHREIBER, Anne K. et al. Diabetic neuropathic pain: physiopathology and treatment. World journal of diabetes, v. 6, n. 3, p. 432, 2015.
SUN, Feng et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes technology & therapeutics, v. 17, n. 1, p. 35-42, 2015.
TRIKKALINOU, Aikaterini; PAPAZAFIROPOULOU, Athanasia K.; MELIDONIS, Andreas. Type 2 diabetes and quality of life. World journal of diabetes, v. 8, n. 4, p. 120, 2017.
VALAIYAPATHI, Badhma; GOWER, Barbara; ASHRAF, Ambika P. Pathophysiology of type 2 diabetes in children and adolescents. Current diabetes reviews, v. 16, n. 3, p. 220-229, 2020.
ZHANG, Yanqing et al. GLP-1 receptor in pancreatic α-cells regulates glucagon secretion in a glucose-dependent bidirectional manner. Diabetes, v. 68, n. 1, p. 34-44, 2019.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Matheus Oliveira de Macedo , Laureane Silva Leal , Lucas Veo Gusmão , Gabriela Oliveira Vilela , Ana Júlia de Melo Agustini , Gabrielle Maria Amélia Fuzato , Maria Clara de Andrade Viana , Joyce de Almeida Nogueira
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Termo de cess